Csóka K, Tholander B, Gerdin E, de la Torre M, Larsson R, Nygren P
Division of Clinical Pharmacology, University Hospital, Uppsala, Sweden.
Int J Cancer. 1997 Sep 17;72(6):1008-12. doi: 10.1002/(sici)1097-0215(19970917)72:6<1008::aid-ijc15>3.0.co;2-0.
The fluorometric microculture cytotoxicity assay (FMCA), a short-term in vitro assay based on the concept of total tumor cell kill, was used for testing the cytotoxic drug sensitivity of tumor cells from patients with ovarian carcinoma. A total of 125 fresh specimens was obtained, 98 (78%) of which were analyzed successfully. Data from 45 patients were available for clinical correlations. The FMCA appeared to yield clinically relevant cytotoxic drug sensitivity data for ovarian carcinoma as indicated by a comparison with tumor samples obtained from patients with non-Hodgkin's lymphoma or kidney carcinoma. Considering the most active single agent in vitro actually given in vivo, and using the median drug activity among all ovarian carcinoma samples as a cut-off, the sensitivity of the assay and its specificity were 75 and 52%, respectively. Cross-resistance in vitro was frequently observed between standard drugs but not between standard drugs and Taxol. Ten percent of the specimens showed an extreme resistance for at least 4 of 6 of the drugs investigated.
荧光微量培养细胞毒性试验（FMCA）是一种基于肿瘤细胞全部杀灭概念的短期体外试验，用于检测卵巢癌患者肿瘤细胞的细胞毒性药物敏感性。共获取了125份新鲜标本，其中98份（78%）成功进行了分析。45例患者的数据可用于临床相关性分析。与从非霍奇金淋巴瘤或肾癌患者获取的肿瘤样本相比，FMCA似乎能得出与卵巢癌临床相关的细胞毒性药物敏感性数据。考虑到实际在体内给予的最具活性的单一药物，并以所有卵巢癌样本中的药物活性中位数作为临界值，该试验的敏感性和特异性分别为75%和52%。标准药物之间经常观察到体外交叉耐药，但标准药物与紫杉醇之间未观察到。10%的标本对所研究的6种药物中的至少4种表现出极端耐药。
